StockSelector.com
  Research, Select, & Monitor Thursday, April 19, 2018 6:53:47 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Protalix BioTherapeutics Inc$0.44($.01)(2.22%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Protalix BioTherapeutics Inc has an overall rank of 3388 out of 6928 stocks based on 7 positive rankings and 7 negative rankings.

Positive Rankings
PEGValue
Protalix BioTherapeutics Inc has a PEG Value of $21.89. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 4,765.49% in the next year. Among companies with a PEG Value above the current stock price, Protalix BioTherapeutics Inc is ranked 12.
Low vPut/Call
Protalix BioTherapeutics Inc has a low Put/Call ratio of 0.04 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Protalix BioTherapeutics Inc is ranked 80.
Estimated Revenue Growth
Protalix BioTherapeutics Inc rank is 88
Low Put/Call
Protalix BioTherapeutics Inc has a low Put/Call ratio of 0.08 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Protalix BioTherapeutics Inc is ranked 165.
SSValue
The StockSelector Value for Protalix BioTherapeutics Inc is $1.87. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Protalix BioTherapeutics Inc is ranked 333.
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Protalix BioTherapeutics Inc is ranked 1228.
10 Day Gain
Protalix BioTherapeutics Inc rank is 2262
Negative Rankings
Negative ROA
Protalix BioTherapeutics Inc rank is 171
Negative Net Margin
Protalix BioTherapeutics Inc rank is 234
90 Day Loss
Protalix BioTherapeutics Inc rank is 338
Negative Revenue Growth
Protalix BioTherapeutics Inc rank is 343
Down EPS Surprise
Protalix BioTherapeutics Inc missed the consensus earnings estimate when it last reported quarterly earnings.
Negative Cash Growth
Protalix BioTherapeutics Inc rank is 1174
Price-to-Sales
Protalix BioTherapeutics Inc rank is 1718







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.